Hormone Replacement Therapy in Premenopausal Women After Bilateral Oophorectomy

Introduction to HRT

The American College of Obstetricians and Gynecologists recommends hormone replacement therapy (HRT) for women who undergo bilateral oophorectomy before natural menopause to minimize long-term health consequences, including cardiovascular disease, osteoporosis, and cognitive decline 1

Vasomotor symptoms, mood changes, sleep disturbance, vaginal dryness, and sexual dysfunction develop rapidly in women after bilateral oophorectomy, highlighting the need for prompt HRT initiation 1

HRT should be initiated immediately after bilateral oophorectomy and continued until at least age 51 to minimize long-term health consequences, according to the North American Menopause Society 1
Estrogen-only therapy is the optimal hormonal management for women with concurrent hysterectomy, as it has a more favorable safety profile and may even reduce breast cancer risk 1
Estrogen must be combined with progestogen to protect against endometrial hyperplasia and cancer in women without hysterectomy, as recommended by the American College of Obstetricians and Gynecologists 1

For women with BRCA mutations or Lynch syndrome undergoing risk-reducing bilateral salpingo-oophorectomy, HRT is strongly recommended to prevent bone, cardiovascular, and quality of life deterioration, as suggested by the National Comprehensive Cancer Network 1, 2
The timing of risk-reducing bilateral salpingo-oophorectomy should be individualized, with MSH2/MLH1 carriers considered around age 35 and MSH6 carriers after age 40, according to the Society of Gynecologic Oncology 2

Premenopausal women with hormone receptor-positive metastatic breast cancer require ovarian suppression or ablation combined with endocrine therapy, as recommended by the American Society of Clinical Oncology 3
GnRH agonists are an acceptable alternative to surgical oophorectomy for therapeutic ovarian suppression, but adequate ovarian suppression must be confirmed, as suggested by the European Society for Medical Oncology 3, 4

Monitor estradiol and FSH/LH levels in women under 60 who are amenorrheic for ≤12 months prior to adjuvant endocrine therapy, as recommended by the National Comprehensive Cancer Network 6
Use high-sensitivity estradiol assays to confirm adequate suppression when combining GnRH agonists with aromatase inhibitors, as suggested by the American Society of Clinical Oncology 4, 5

Selective serotonin reuptake inhibitors (SSRIs) like citalopram or serotonin-norepinephrine reuptake inhibitors (SNRIs) like venlafaxine have minimal drug interactions and can be used as non-hormonal options for managing menopausal symptoms, as recommended by the North American Menopause Society 7
Fertility preservation counseling, including options such as cryopreservation of embryos or oocytes, should be discussed before surgery, as suggested by the American Society for Reproductive Medicine 4, 5